Multi-objective routing and scheduling for relief distribution with split delivery in post-disaster response

Abstract Following the occurrence of unexpected events and natural disasters, a highly important relief operation is the transferring of relief commodities from the distribution centers (DCs) to shelters. In this paper, a three-level network consisting of depot of vehicles, distribution centers,and shelters has been considered for routing and scheduling of relief vehicles through introducing a multi-objective model. The first objective function represents the total arrival time of vehicles to DCs and shelters. The second objective function illustrates the number of vehicles used. We use the TH method to deal with the multi-objective problem. During the relief commodities distribution, issues such as the feasibility of getting service from each distribution center with multiple vehicles and heterogeneous fleet of vehicles has been regarded. In order to solve the proposed model and represent its efficiency, we select the fourth region of Tehran city as a case study; run the model on it, and present solution results. Keywords: Disaster Management, Multi-objective optimization, Routing, Scheduling 1-Introduction The occurrence of natural and man-made disasters such as flood, earthquake, thunderstorm, etc. would cause drastic social and economic damages, as well as the displacement and even the death of thousands of people. Accordingly, in order to lower the casualties and economic losses in these disasters, certain relief operations should be considere

Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells.

Differentiation therapy is attracting increasing interest in cancer as it can be more specific than conventional chemotherapy approaches, and it has offered new treatment options for some cancer types, such as treating acute promyelocytic leukaemia (APL) by retinoic acid. However, there is a pressing need to identify additional molecules which act in this way, both in leukaemia and other cancer types. In this work, we hence developed a novel transcriptional drug repositioning approach, based on both bioinformatics and cheminformatics components, that enables selecting such compounds in a more informed manner. We have validated the approach for leukaemia cells, and retrospectively retinoic acid was successfully identified using our method. Prospectively, the anti-parasitic compound fenbendazole was tested in leukaemia cells, and we were able to show that it can induce the differentiation of leukaemia cells to granulocytes in low concentrations of 0.1 μM and within as short a time period as 3 days. This work hence provides a systematic and validated approach for identifying small molecules for differentiation therapy in cancer

New implementation of hashing and encoding in digital signature

The purpose of introducing of this algorithm is a new method for designing a simple mechanism for producing a digital signature. Some applications like multi agent systems transfer messages with low size and capacity. The new algorithm minimizes the size of original file and gives us a dynamic and smaller size output. In this algorithm read the input file then hash the message and encode it. Finally modify the established code into a unique ID at Base 16. We concentrate on designing and implementation of functions of algorithm

Enhancing secured data hiding using dynamic digital signature for authentication purpose

As a significant verification method, digital signature algorithm introduces a technique to endorse what the contents of the message. This message has not been altered throughout the communication process. Due to this, it increases the receiver confidence that the message was unchanged. However, two issues that required to be addressed are large size of the ciphered data in digital signature and making it closer to the original file. The objective of this paper is to present the adoption of digital signature as a stegano-image into the main image and the LSB steganographic method is capable to increase the security. The benefits of this encryption algorithm are computational efficiency, digital signature with the size as small as 8 bytes and minimize bandwidth in comparison with other digital signature methods. In messages with the sizes smaller than 1600 bytes, the hashed file reduces the original file up to 8.51%

The impact of platelet-to-lymphocyte ratio on clinical outcomes in heart failure: a systematic review and meta-analysis

Background: Inflammation has been suggested to play a role in heart failure (HF) pathogenesis. However, the role of platelet-to-lymphocyte ratio (PLR), as a novel biomarker, to assess HF prognosis needs to be investigated. We sought to evaluate the impact of PLR on HF clinical outcomes. Methods: English-published records in PubMed/Medline, Scopus, and Web-of-science databases were screened until December 2023. Relevant articles evaluated PLR with clinical outcomes (including mortality, rehospitalization, HF worsening, and HF detection) were recruited, with PLR difference analysis based on death/survival status in total and HF with reduced ejection fraction (HFrEF) patients. Results: In total, 21 articles ( n  = 13,924) were selected. The total mean age was 70.36 ± 12.88 years (males: 61.72%). Mean PLR was 165.54 [95% confidence interval (CI): 154.69–176.38]. In total, 18 articles ( n  = 10,084) reported mortality [either follow-up (PLR: 162.55, 95% CI: 149.35–175.75) or in-hospital (PLR: 192.83, 95% CI: 150.06–235.61) death rate] and the mean PLR was 166.68 (95% CI: 154.87–178.50). Further analysis revealed PLR was significantly lower in survived HF patients rather than deceased group (152.34, 95% CI: 134.01–170.68 versus 194.73, 95% CI: 175.60–213.85, standard mean difference: −0.592, 95% CI: −0.857 to −0.326, p  < 0.001). A similar trend was observed for HFrEF patients. PLR failed to show any association with mortality risk (hazard ratio: 1.02, 95% CI: 0.99–1.05, p  = 0.289). Analysis of other aforementioned outcomes was not possible due to the presence of few studies of interest. Conclusion: PLR should be used with caution for prognosis assessment in HF sufferers and other studies are necessary to explore the exact association

Role of ZEB family members in proliferation, metastasis, and chemoresistance of prostate cancer cells: revealing signaling networks

Prostate cancer (PCa) is one of the leading causes of death worldwide. A variety of strategies, including surgery, chemotherapy, radiotherapy, and immunotherapy, are applied for PCa treatment. PCa cells are responsive towards therapy at early stages, but they can obtain resistance in the advanced stage. Furthermore, their migratory ability is high in advanced stages. It seems that genetic and epigenetic factors play an important role in this case. Zinc finger E-box-binding home-obox (ZEB) is a family of transcription with two key members, including ZEB1 and ZEB2. ZEB family members are known due to their involvement in promoting cancer metastasis via EMT induction. Recent studies have shown their role in cancer proliferation and inducing therapy resistance. In the current review, we focus on revealing the role of ZEB1 and ZEB2 in PCa. ZEB family members are able to significantly promote the proliferation and viability of cancer cells. ZEB1 and ZEB2 enhance migration and invasion of PCa cells via EMT induction. Overexpression of ZEB1 and ZEB2 is associated with a poor prognosis of PCa. ZEB1 and ZEB2 upregulation occurs during PCa progression and can provide therapy resistance to cancer cells. PRMT1, Smad2, and non-coding RNAs can function as upstream mediators of the ZEB family. Besides, Bax, Bcl-2, MRP1, N-cadherin, and E-cadherin can be considered as downstream targets of the ZEB family in PCa

Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells

Abstract Differentiation therapy is attracting increasing interest in cancer as it can be more specific than conventional chemotherapy approaches, and it has offered new treatment options for some cancer types, such as treating acute promyelocytic leukaemia (APL) by retinoic acid. However, there is a pressing need to identify additional molecules which act in this way, both in leukaemia and other cancer types. In this work, we hence developed a novel transcriptional drug repositioning approach, based on both bioinformatics and cheminformatics components, that enables selecting such compounds in a more informed manner. We have validated the approach for leukaemia cells, and retrospectively retinoic acid was successfully identified using our method. Prospectively, the anti-parasitic compound fenbendazole was tested in leukaemia cells, and we were able to show that it can induce the differentiation of leukaemia cells to granulocytes in low concentrations of 0.1 μM and within as short a time period as 3 days. This work hence provides a systematic and validated approach for identifying small molecules for differentiation therapy in cancer

sj-doc-2-tak-10.1177_17539447241227287 – Supplemental material for The impact of platelet-to-lymphocyte ratio on clinical outcomes in heart failure: a systematic review and meta-analysis

Supplemental material, sj-doc-2-tak-10.1177_17539447241227287 for The impact of platelet-to-lymphocyte ratio on clinical outcomes in heart failure: a systematic review and meta-analysis by Mehrbod Vakhshoori, Niloofar Bondariyan, Sadeq Sabouhi, Keivan Kiani, Nazanin Alaei Faradonbeh, Sayed Ali Emami, Mehrnaz Shakarami, Farbod Khanizadeh, Shahin Sanaei, Niloofaralsadat Motamedi and Davood Shafie in Therapeutic Advances in Cardiovascular Disease</p